$125 Million

Immunomedics, Inc.

PIPE

Sole Placement Agent, May 2017

Immunomedics, Inc.
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxicities that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU- 132) and labetuzumab govitecan (IMMU-130), which are being studied for a number of solid tumors and metastatic colorectal cancer, respectively.